Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Business Of Biotech
00:00
The Problem With the Growth of Biopharma Companies
Do you see a problem in the industry around companies that perhaps aren't as rooted in that long term study and research that you brought to the table? I've seen, yes, I have seen some facets that I didn't like too much. And that was going to decisions which were probably involving too many people, too many financial efforts for very for not so good expectations at to start with.
Transcript
Play full episode
